Search

Your search keyword '"Greillier, L"' showing total 311 results
Start Over Author "Greillier, L" Search Limiters Full Text
311 results on '"Greillier, L"'

1. Osimertinib treatment based on plasma T790M monitoring in patients with EGFR-mutant non-small-cell lung cancer (NSCLC): EORTC Lung Cancer Group 1613 APPLE phase II randomized clinical trial

Author

Remon, J., Besse, B., Aix, S. Ponce, Callejo, A., Al-Rabi, K., Bernabe, R., Greillier, L., Majem, M., Reguart, N., Monnet, I., Cousin, S., Garrido, P., Robinet, G., Garcia Campelo, R., Madroszyk, A., Mazières, J., Curcio, H., Wasąg, B., Pretzenbacher, Y., Fournier, B., Dingemans, A.-M.C., and Dziadziuszko, R.

Published
2023
Full Text
View/download PDF

3. The Value of Population Screening in Advancing Personalized Medicine in the Field of Lung Cancer

Author

Mogenet A, Greillier L, and Tomasini P

Subjects
molecular biology – targeted therapy – lung cancer – immunotherapy – biomarkers, Therapeutics. Pharmacology, RM1-950
Abstract

Alice Mogenet, Laurent Greillier, Pascale Tomasini Aix Marseille University, CNRS, INSERM, CRCM, APHM, Multidisciplinary Oncology & Therapeutic Innovations Department, Marseille, FranceCorrespondence: Pascale TomasiniService d’Oncologie Multidisciplinaire et Innovations Thérapeutiques, Hôpital Nord, Chemin des Bourrely, Marseille Cedex, 13915, FranceTel +33 4 91 96 59 01Fax +33 4 91 96 59 02Email pascale.tomasini@ap-hm.frAbstract: During the past decade, progress has been made in the field of lung cancer molecular biology and onco-immunology, leading to prolonged survival of patients. The combination of increased fundamental knowledge and the pharmaceutical pipeline has allowed the development of various tyrosine kinase inhibitors, targeting numerous molecular alterations. These drugs are now available in daily practice and have transformed survival outcomes for patients harboring EGFR, ALK or ROS1 alterations. Multiple clinical trials are now ongoing in order to increase the number of approved drugs, thus overcoming the issues of rare mutations and tyrosine kinase inhibitors resistance. Immune checkpoint inhibitors development has also changed lung cancer outcomes, but underwhelming response rates highlight the need for immune biomarkers. While PD-L1 expression was the first approved immune biomarker, it has shown several limitations and new biomarkers have to be identified to predict response or resistance to immune checkpoint inhibitors. Testing methods, molecular results and targeted therapeutic schedules will be harmonized in the coming years, with the help of dedicated molecular multidisciplinary boards.Keywords: molecular biology, targeted therapy, lung cancer, immunotherapy, biomarkers

Published
2021

4. Medication Reconciliation Associated with Comprehensive Geriatric Assessment in Older Patients with Cancer: ChimioAge Study

Author

Couderc AL, Boisseranc C, Rey D, Nouguerede E, Greillier L, Barlesi F, Duffaud F, Deville L, Honoré S, Villani P, and Correard F

Subjects
aged, antineoplastic protocols, geriatric assessment, medication reconciliation, treatment failure, Geriatrics, RC952-954.6
Abstract

Anne-Laure Couderc,1,2 Celia Boisseranc,3 Dominique Rey,1 Emilie Nouguerede,1 Laurent Greillier,4,5 Fabrice Barlesi,4,5 Florence Duffaud,4,6 Jean-Laurent Deville,6 Stéphane Honoré,3,4 Patrick Villani,1,2 Florian Correard3,4 1Internal Medicine, Geriatry and Therapeutic Unit, AP-HM, Marseille, France;Coordination Unit for Geriatric Oncology (UCOG), PACA West, Marseille, France; 2Aix-Marseille Université, CNRS, EFS, ADES, Marseille, France; 3Pharmacology Department, AP-HM, Marseille, France; 4Aix-Marseille University, Marseille, France; 5Multidisciplinary Oncology and Therapeutic Innovations Unit, AP-HM, Marseille, France; 6Oncology Unit, AP-HM, Marseille, FranceCorrespondence: Anne-Laure CoudercCoordination Unit for Geriatric Oncology (UCOG), PACA West, University Hospital of Marseille (AP-HM), 270 Boulevard De Sainte Marguerite, Marseille 13009, FranceTel +33 491744530Fax +33 491744833Email anne-laure.couderc@ap-hm.frBackground: Polymorbidity induces polypharmacy in older patients may lead to potential drug–drug interactions (DDI) which can modify the tolerance and safety of oncological treatments and alter the intended therapeutic effect. The objective of our study was to describe the decision-making process for oncological treatment and related outcomes, in a population of older adults undergoing a comprehensive geriatric assessment (CGA) associated to a comprehensive medication reconciliation (CMR) prior to initiating oncological treatment.Methods: ChimioAge is a prospective observational study conducted between 01/2017 and 07/2018 at Marseille University Hospital and approved by the French National Ethics Committee. It comprised all consecutive patients aged 70 years and over who were referred for a CGA as part of CMR, before initiating systemic treatment.Results: One hundred and seventy-one cancer patients were included. Mean age was 79.2 years, over half had metastatic cancers, 75% had an ECOG performance status zero or one, and two-thirds were independent in daily activities. Two-thirds of the patients had polypharmacy and the CMR identified potential DDI with systemic treatment in 43.3% of patients. Following the CGA, the CMR and the hospital oncologists decision, 30% of the patients received adapted systemic treatment with reduced doses at initiation. They presented fewer toxicities – irrespective of grade and type – than patients who received standard treatment (p< 0.001) and had comparable overall survival (Log rank p=0.21).Conclusion: This is one of the first studies to highlight the value in conducting CMR and a CGA simultaneously before initiating systemic treatment in older patients with cancer. These two evaluations could give oncologists decisive information to personalize cancer treatment of older patients and optimize treatment dose to offer the best efficacy and minimize toxicity.Keywords: aged, antineoplastic protocols, geriatric assessment, medication reconciliation, treatment failure

Published
2020

5. 179P Integrating multiplex immunofluorescence with gene expression data in the IMMUcan HER2-positive breast cancer cohort

Author

Rediti, M., primary, Garcia, A. Joaquin, additional, Tissot, S., additional, Rusakiewicz, S., additional, Despland, L., additional, Morfouace, M., additional, Liechti, R., additional, Marzetta, F., additional, Oliveira, J., additional, Goeminne, J-C., additional, Marques, A. Capela, additional, Greillier, L., additional, Wang, X., additional, Vincent, D., additional, Hong, H.S., additional, Cesaroni, M., additional, Sotiriou, C., additional, and Buisseret, L., additional

Published
2023
Full Text
View/download PDF

7. 10 Osimertinib versus gefitinib followed by osimertinib in patients with EGFR-mutant non-small cell lung cancer (NSCLC): EORTC Lung Cancer Group 1613 APPLE trial

Author

Masip, J. Remon, primary, Besse, B., additional, Aix, S. Ponce, additional, Perez, A. Callejo, additional, Al-Rabi, K., additional, Caro, R. Bernabe, additional, Greillier, L., additional, Tarruella, M. Majem, additional, Aransay, N. Reguart, additional, Monnet, I., additional, Cousin, S., additional, Lopez, P. Garrido, additional, Robinet, G., additional, Campelo, R. García, additional, Flandin, A-C. Madroszyk, additional, Mazieres, J., additional, Curcio, H., additional, Pretzenbacher, Y., additional, Dingemans, A-M.C., additional, and Dziadziuszko, R., additional

Published
2023
Full Text
View/download PDF

8. 3MO Comprehensive biomarkers (BMS) analysis to predict efficacy of PD1/L1 immune checkpoint inhibitors (ICIs) in combination with chemotherapy: A subgroup analysis of the precision immuno-oncology for advanced non-small cell lung cancer (pioneer) trial

Author

Barlesi, F., primary, Greillier, L., additional, Monville, F., additional, Audigier Valette, C., additional, Martinez, S., additional, Cloarec, N., additional, Van Hulst, S., additional, Odier, L., additional, Vely, F., additional, Juquel, L., additional, Arnaud, L., additional, Bokobza, S., additional, Hamimed, M., additional, Karlsen, M., additional, Dufosse, P., additional, Pouchin, A., additional, Ghezali, L., additional, Le Ray, M., additional, Fieschi-Meric, J., additional, and Benzekry, S., additional

Published
2022
Full Text
View/download PDF

9. EE608 Cost Effectiveness Analysis of a Large (Foundation Medicine) Versus a Home-Based Medium Gene Panel for Exome Sequencing: Results of the Profiler 02 Randomized Clinical Trial

Author

Perrier, L, primary, Tredan, O, additional, Morelle, M, additional, Penel, N, additional, Fournel, P, additional, Greillier, L, additional, Ghiringhelli, F, additional, Tosi, D, additional, Bertucci, F, additional, Campone, M, additional, Delord, JP, additional, Pouessel, D, additional, Garin, G, additional, Chabaud, S, additional, Gomez-Roca, C, additional, Pannier, D, additional, Brahmi, M, additional, Fabbro, M, additional, Garcia, ME, additional, Ray-Coquard, I, additional, Viala, M, additional, Italiano, A, additional, Cassier, P, additional, Dufresne, A, additional, Attignon, V, additional, Treilleux, I, additional, Viari, A, additional, de la Motte Rouge, T, additional, Durando, X, additional, Perol, D, additional, and Blay, JY, additional

Published
2022
Full Text
View/download PDF

10. Quality of life at diagnosis for unresectable stage III NSCLC: Initial results from the national prospective study OBSTINATE (GFPC 06-2019)

Author

Ricordel, C, Anota, A., Bernardi, M., Falchero, L, Auliac, J. B., Greillier, L, Bylicki, O., de Chabot, G., Demaegdt, A., Vergnenegre, A, Decroisette, C, Martel-Lafay, I., Chouaid, C, Guisier, F., Oncogenesis, Stress, Signaling (OSS), Université de Rennes (UR)-CRLCC Eugène Marquis (CRLCC)-Institut National de la Santé et de la Recherche Médicale (INSERM), Centre Léon Bérard [Lyon], Laboratoire d'Informatique, de Traitement de l'Information et des Systèmes (LITIS), Université Le Havre Normandie (ULH), Normandie Université (NU)-Normandie Université (NU)-Université de Rouen Normandie (UNIROUEN), Normandie Université (NU)-Institut national des sciences appliquées Rouen Normandie (INSA Rouen Normandie), Institut National des Sciences Appliquées (INSA)-Normandie Université (NU)-Institut National des Sciences Appliquées (INSA), and AstraZeneca

Subjects
[SDV.CAN]Life Sciences [q-bio]/Cancer
Abstract

International audience

Published
2022
Full Text
View/download PDF

11. 1176P Open-label, dose escalation, phase I/II study to assess safety, tolerability, immunogenicity and preliminary clinical activity of the therapeutic cancer vaccine PDC*lung01 with or without anti-programmed death-1 (PD-1) treatment in patients with non-small cell lung cancer (NSCLC)

Author

Vansteenkiste, J.F., primary, Demedts, I., additional, Pons-Tostivint, E., additional, Biesma, B., additional, Borm, F., additional, Colinet, B., additional, Cuppens, K., additional, Derijcke, S., additional, Greillier, L., additional, Jürgens, J., additional, Moro-Sibilot, D., additional, Pérol, M., additional, Sebastian, M., additional, Skrzypski, M., additional, Theelen, W., additional, Van De Kerkhove, C., additional, Collodoro, M., additional, Plumas, J., additional, Debruyne, C., additional, and Sibille, A., additional

Published
2022
Full Text
View/download PDF

12. LBA51 Osimertinib treatment based on plasma T790M monitoring in patients with EGFR-mutant non-small cell lung cancer (NSCLC): EORTC Lung Cancer Group 1613 APPLE phase II randomized clinical trial

Author

Masip, J. Remon, primary, Besse, B., additional, Aix, S. Ponce, additional, Callejo, A., additional, Al-Rabi, K., additional, Caro, R. Bernabe, additional, Greillier, L., additional, Tarruella, M. Majem, additional, Aransay, N. Reguart, additional, Monnet, I., additional, Cousin, S., additional, Lopez, P. Garrido, additional, Robinet, G., additional, Campelo, M.R. Garcia, additional, Flandin, A-C. Madroszyk, additional, Mazieres, J., additional, Pretzenbacher, Y., additional, Fournier, B., additional, Dingemans, A-M.C., additional, and Dziadziuszko, R., additional

Published
2022
Full Text
View/download PDF

13. 1035P A phase II trial of nivolumab and denosumab association as second-line treatment for stage IV non-small-cell lung cancer (NSCLC) with bone metastases: DENIVOS study (GFPC 06-2017)

Author

Decroisette, C., primary, Monnet, I., additional, Ricordel, C., additional, Demaegdt, A., additional, Falchero, L., additional, Bylicki, O., additional, Geier, M., additional, Justeaux, G., additional, Bernardi, M., additional, Andre, M., additional, Guisier, F., additional, Fournel, P., additional, Vieillot, S., additional, Hauss, P.A., additional, Schott, R., additional, Crequit, J., additional, Auliac, J.B., additional, Chouaid, C., additional, and Greillier, L., additional

Published
2022
Full Text
View/download PDF

14. 1640TiP PECATI: A phase II trial to evaluate the efficacy and safety of lenvatinib in combination with pembrolizumab in pretreated advanced b3-thymoma (B3-T) and thymic carcinoma (TC)

Author

Remon Masip, J., primary, Girard, N., additional, Bironzo, P., additional, Novello, S., additional, De Castro Carpeno, J., additional, Bigay-Game, L., additional, Bernabe Caro, R., additional, Greillier, L., additional, Mosquera Martinez, J., additional, Cousin, S., additional, Juan Vidal, O.J., additional, Sampayo-Cordero, M., additional, and Besse, B., additional

Published
2022
Full Text
View/download PDF

15. 1097P Impact of tumor and liquid rebiopsy in metastatic non-small cell lung cancer with EGFR/ALK/ROS oncogenic drivers, progressing after optimal target therapy

Author

Bronstein, A., primary, Gervais, R., additional, Monnet, I., additional, Ricordel, C., additional, Bigay-Game, L., additional, Geier, M., additional, Decroisette, C., additional, Daniel, C., additional, Guisier, F., additional, Swalduz, A., additional, Toffart, A.C., additional, Doubre, H., additional, Peloni, J.M., additional, Arpin, D., additional, Morel, H., additional, Veillon, R., additional, Clarisse, B., additional, Chouaid, C., additional, Greillier, L., additional, and Bylicki, O., additional

Published
2022
Full Text
View/download PDF

16. LBA71 First-line nivolumab (NIVO) plus ipilimumab (IPI) vs chemotherapy (chemo) in patients (pts) with unresectable malignant pleural mesothelioma (uMPM): 4-year update from CheckMate 743

Author

Zalcman, G., primary, Oulkhouir, Y., additional, Cornelissen, R., additional, Greillier, L., additional, Cid, J.R. Rodriguez, additional, Mazieres, J., additional, Briggs, P., additional, Nowak, A.K., additional, Tsao, A., additional, Fujimoto, N., additional, Peters, S., additional, Mansfield, A.S., additional, Popat, S., additional, Nassar, A., additional, Bushong, J., additional, Hu, N., additional, Spires, T., additional, Balli, D., additional, Eccles, L., additional, and Baas, P., additional

Published
2022
Full Text
View/download PDF

17. 1154P Geriatrics predictors of 3-months overall survival and chemotherapy toxicities in older patients with metastatic non-small cell lung cancer

Author

Gendarme, S., primary, Zebachi, S., additional, Corre, R., additional, Greillier, L., additional, Justeau, G., additional, Bylicki, O., additional, Decroisette, C., additional, Auliac, J.B., additional, Guisier, F., additional, Geier, M., additional, Ricordel, C., additional, Frelaut, M., additional, Paillaud, E., additional, Chouaid, C., additional, and Canouï-Poitrine, F., additional

Published
2022
Full Text
View/download PDF

18. 1016P GFPC 06-2018: A multicentre phase II, open-label, non-randomized study evaluating platinum-pemetrexed-atezolizumab (+/- bevacizumab) for patients with stage IIIB/IV non-squamous NSCLC with EGFR mutation, ALK rearrangement or ROS1 fusion progressing after targeted therapies

Author

Bylicki, O., primary, Gervais, R., additional, Monnet, I., additional, Ricordel, C., additional, Bigay-Game, L., additional, Geier, M., additional, Decroisette, C., additional, Daniel, C., additional, Guisier, F., additional, Swalduz, A., additional, Toffart, A.C., additional, Doubre, H., additional, Peloni, J.M., additional, Arpin, D., additional, Morel, H., additional, Veillon, R., additional, Clarisse, B., additional, Martins-Lavinas, P-H., additional, Greillier, L., additional, and Chouaid, C., additional

Published
2022
Full Text
View/download PDF

19. 1106P Capmatinib for METex14 non-small cell lung cancer patients: Results of the real-world study IFCT-2104 CapmATU

Author

Ferreira, M., primary, Greillier, L., additional, Swalduz, A., additional, Toffart, A.C., additional, Raimbourg, J., additional, Gounant, V., additional, Couraud, S., additional, De Chabot, G., additional, Friard, S., additional, Hureaux, J., additional, Odier, L., additional, Wislez, M., additional, Missy, P., additional, Morin, F., additional, Westeel, V., additional, and Cortot, A., additional

Published
2022
Full Text
View/download PDF

20. 962P Quality of life at diagnosis for unresectable stage III NSCLC: Initial results from the national prospective study OBSTINATE (GFPC 06-2019)

Author

Ricordel, C., primary, Anota, A., additional, Bernardi, M., additional, Falchero, L., additional, Auliac, J.B., additional, Greillier, L., additional, Bylicki, O., additional, De Chabot, G., additional, Demaegdt, A., additional, Vergnenegre, A., additional, Decroisette, C., additional, Martel-Lafay, I., additional, Chouaid, C., additional, and Guisier, F., additional

Published
2022
Full Text
View/download PDF

21. From randomized trials to the clinic: is it time to implement individual lung-cancer screening in clinical practice? A multidisciplinary statement from French experts on behalf of the french intergroup (IFCT) and the groupe d'Oncologie de langue française (GOLF)

Author

Couraud, S., Cortot, A.B., Greillier, L., Gounant, V., Mennecier, B., Girard, N., Besse, B., Brouchet, L., Castelnau, O., Frappé, P., Ferretti, G.R., Guittet, L., Khalil, A., Lefebure, P., Laurent, F., Liebart, S., Molinier, O., Quoix, E., Revel, M.-P., Stach, B., Souquet, P.-J., Thomas, P., Trédaniel, J., Lemarié, E., Zalcman, G., Barlési, F., and Milleron, B.

Published
2013
Full Text
View/download PDF

22. Exercise in lung Cancer, the healthcare providers opinion (ECHO): Results of the EORTC lung cancer Group (LCG) survey

Author

Pilotto, S., Avancini, A., Menis, J., Sperduti, I., Levra, M.G., Berghmans, T., Bironzo, P., Brandao, M., De Ruysscher, D., Edwards, J., Faivre-Finn, C., Girard, N., Greillier, L., Hendriks, L., Lantuejoul, S., Mauer, M., Novello, S., O'Brien, M., Reck, M., Reguart, N., Remon, J., von der Thusen, J., Dingemans, A.M.C., Besse, B., Milella, M., Pilotto, S., Avancini, A., Menis, J., Sperduti, I., Levra, M.G., Berghmans, T., Bironzo, P., Brandao, M., De Ruysscher, D., Edwards, J., Faivre-Finn, C., Girard, N., Greillier, L., Hendriks, L., Lantuejoul, S., Mauer, M., Novello, S., O'Brien, M., Reck, M., Reguart, N., Remon, J., von der Thusen, J., Dingemans, A.M.C., Besse, B., and Milella, M.

Abstract

Objectives: Exercise has been reported to alleviate disease as well as treatment impact in patients with lung cancer. Nevertheless, there is limited information available regarding the perception of lung cancer dedicated healthcare professionals' and their advice on exercise. Materials and Methods: An online survey exploring healthcare professionals' practice patterns, perceptions, barriers, and facilitators of exercise in patients with lung cancer was conducted within members of the EORTC Lung Cancer Group (LCG).Results: One hundred forty-one healthcare providers completed the survey, mainly medical and radiation oncologists. Overall, 63% of the study participants declared that they frequently assessed exercise level in their patients, and 43% of them reinforced the importance of exercise. However, only 10% referred patients to an exercise program or specialist. Although the majority of the respondents had a positive perception regarding the benefits and safety of exercise (even in patients with advanced disease and/or bone metastasis), two-thirds of clinicians reported not having adequate training about exercise counselling. Moreover, 53% reported to lack of knowledge of guidelines referring to exercise in patients with cancer. Several obstacles and facilitators to improve exercise promotion in lung cancer care were identified.Conclusion: Healthcare providers recognize the relevance and feasibility of exercise as part of cancer treatment intervention, but specific pathways to do the referral are frequently missing. Future structured and well-designed strategies and initiatives are needed to support an effective referral in order to implement exercise interventions routinely in clinical practice.

Published
2022

23. First-line nivolumab plus ipilimumab versus chemotherapy in patients with unresectable malignant pleural mesothelioma:3-year outcomes from CheckMate 743

Author

Peters, S., Scherpereel, A., Cornelissen, R., Oulkhouir, Y., Greillier, L., Kaplan, M. A., Talbot, T., Monnet, I., Hiret, S., Baas, P., Nowak, A. K., Fujimoto, N., Tsao, A. S., Mansfield, A. S., Popat, S., Zhang, X., Hu, N., Balli, D., Spires, T., Zalcman, G., Peters, S., Scherpereel, A., Cornelissen, R., Oulkhouir, Y., Greillier, L., Kaplan, M. A., Talbot, T., Monnet, I., Hiret, S., Baas, P., Nowak, A. K., Fujimoto, N., Tsao, A. S., Mansfield, A. S., Popat, S., Zhang, X., Hu, N., Balli, D., Spires, T., and Zalcman, G.

Abstract

Background: In the phase III CheckMate 743 study (NCT02899299), first-line nivolumab plus ipilimumab significantly improved overall survival (OS) versus chemotherapy in patients with unresectable malignant pleural mesothelioma (MPM). We report updated data with 3-year minimum follow-up. Patients and methods: Adults with previously untreated, histologically confirmed, unresectable MPM and Eastern Cooperative Oncology Group performance status of ≤1 were randomized 1: 1 to nivolumab (3 mg/kg every 2 weeks) plus ipilimumab (1 mg/kg every 6 weeks) for up to 2 years, or six cycles of platinum plus pemetrexed chemotherapy. This report includes updated efficacy and safety outcomes, exploratory biomarker analyses including four-gene inflammatory expression signature score, and a post hoc efficacy analysis in patients who discontinued treatment due to treatment-related adverse events (TRAEs). Results: With a median follow-up of 43.1 months, nivolumab plus ipilimumab continued to prolong OS versus chemotherapy. Median OS was 18.1 versus 14.1 months [hazard ratio (95% confidence interval), 0.73 (0.61–0.87)], and 3-year OS rates were 23% versus 15%, respectively. Three-year progression-free survival rates were 14% versus 1%, and objective response rates were 40% versus 44%. At 3 years, 28% versus 0% of responders had an ongoing response. Improved survival benefit with nivolumab plus ipilimumab versus chemotherapy was observed across subgroups, including histology. A high score of the four-gene inflammatory signature appeared to correlate with improved survival benefit with nivolumab plus ipilimumab. No new safety signals were observed with nivolumab plus ipilimumab, despite patients being off therapy for 1 year. In patients who discontinued nivolumab plus ipilimumab due to TRAEs, median OS was 25.4 months, and 34% of responders maintained their responses for ≥3 years after discontinuation. Conclusions: With 3 years’ minimum follow-up, nivolumab plus ipilimumab continued to pr

Published
2022

25. A phase II trial of nivolumab and denosumab association as second-line treatment for stage IV non-small-cell lung cancer (NSCLC) with bone metastases: DENIVOS study (GFPC 06-2017)

Author

Decroisette, C, Monnet, I., Ricordel, C, Demaegdt, A., Falchero, L, Bylicki, O., Geier, M., Justeaux, G., Bernardi, M., Andre, M., Guisier, F., Fournel, P, Vieillot, S., Hauss, P.-A., Schott, R, Crequit, J., Auliac, J. B., Chouaid, C, Greillier, L, Centre Hospitalier Annecy-Genevois [Saint-Julien-en-Genevois], CHI Créteil, Oncogenesis, Stress, Signaling (OSS), Université de Rennes (UR)-CRLCC Eugène Marquis (CRLCC)-Institut National de la Santé et de la Recherche Médicale (INSERM), CHU Pontchaillou [Rennes], Centre Hospitalier Universitaire d'Angers (CHU Angers), PRES Université Nantes Angers Le Mans (UNAM), CHU Rouen, Normandie Université (NU), Institut de Cancérologie de Strasbourg Europe (ICANS), Assistance Publique - Hôpitaux de Marseille (APHM), Centre de Recherche en Cancérologie de Marseille (CRCM), Aix Marseille Université (AMU)-Institut Paoli-Calmettes, Fédération nationale des Centres de lutte contre le Cancer (FNCLCC)-Fédération nationale des Centres de lutte contre le Cancer (FNCLCC)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS), and Amgen

Subjects
[SDV.CAN]Life Sciences [q-bio]/Cancer
Abstract

International audience

Published
2022
Full Text
View/download PDF

27. LBA65 First-line nivolumab (NIVO) plus ipilimumab (IPI) vs chemotherapy (chemo) in patients (pts) with unresectable malignant pleural mesothelioma (MPM): 3-year update from CheckMate 743

Author

Peters, S., primary, Scherpereel, A., additional, Cornelissen, R., additional, Oulkhouir, Y., additional, Greillier, L., additional, Kaplan, M.A., additional, Talbot, T., additional, Monnet, I., additional, Hiret, S., additional, Baas, P., additional, Nowak, A.K., additional, Fujimoto, N., additional, Tsao, A.S., additional, Mansfield, A.S., additional, Popat, S., additional, Zhang, X., additional, Hu, N., additional, Balli, D., additional, Sanzari, J., additional, and Zalcman, G., additional

Published
2021
Full Text
View/download PDF

34. 186TiP An open-label, dose escalation, phase I/II study to assess safety, tolerability, immunogenicity and preliminary clinical activity of the therapeutic cancer vaccine PDC*lung01 with or without anti-programmed death-1 (PD-1) treatment in patients with non-small cell lung cancer (NSCLC)

Author

Bennouna, J., primary, Sibille, A., additional, Debruyne, C., additional, Colinet, B., additional, Demedts, I., additional, Derijcke, S., additional, Greillier, L., additional, Jürgens, J., additional, Lena, H., additional, Moro-Sibilot, D., additional, Perol, M., additional, Quantin, X., additional, Reinmuth, N., additional, Sebastian, M., additional, Genin, M., additional, Plumas, J., additional, and Vansteenkiste, J.F., additional

Published
2021
Full Text
View/download PDF

35. 50P A phase Ib study of CC-90011, a potent, reversible, oral LSD1 inhibitor, plus etoposide and cisplatin (EP) or carboplatin (EC) in patients (Pts) with first-line (1L) extensive-stage (ES) small cell lung cancer (SCLC): Updated results

Author

Aix, S. Ponce, primary, Juan-Vidal, O., additional, Carcereny, E., additional, Trigo, J.M., additional, Provencio, M., additional, Greillier, L., additional, Navarro, A., additional, Bennouna, J., additional, Santoro, A., additional, Berardi, R., additional, Besse, B., additional, Gonzalez, H., additional, de Alvaro, J., additional, Parra-Palau, J.L., additional, Sánchez-Pérez, T., additional, Aronchik, I., additional, Filvaroff, E., additional, Lamba, M., additional, Nikolova, Z., additional, and Paz-Ares, L., additional

Published
2021
Full Text
View/download PDF

38. Diversity of brain metastases screening and management in non-small cell lung cancer in Europe

Author

Levy, A, Faivre-Finn, C, Hasan, B, De Maio, E, Berghoff, As, Girard, N, Greillier, L, Lantuéjoul, S, O'Brien, M, Reck, M, Dingemans, Ac, Novello, S, Berghmans, T, Besse, B, Hendriks, L, Young Investigators EORTC Lung Cancer Group (YI EORTC LCG), RS: GROW - R3 - Innovative Cancer Diagnostics & Therapy, Pulmonologie, MUMC+: MA Med Staf Spec Longziekten (9), and Promovendi ODB

Subjects
0301 basic medicine, Oncology, Cancer Research, Lung Neoplasms, Afatinib, medicine.medical_treatment, DNA Mutational Analysis, MULTICENTER, Guideline, Targeted therapy, 0302 clinical medicine, Carcinoma, Non-Small-Cell Lung, Surveys and Questionnaires, Early Detection of Cancer, Radiation oncologist, Oncologists, POSTOPERATIVE STEREOTACTIC RADIOSURGERY, Radiation, Manchester Cancer Research Centre, Brain Neoplasms, CHEMOTHERAPY, Prognosis, OPEN-LABEL, Europe, 030220 oncology & carcinogenesis, Erlotinib, Lung cancer, PHASE-II TRIAL, Stereotactic radiosurgery, medicine.drug, RADIOTHERAPY, medicine.medical_specialty, 03 medical and health sciences, Gefitinib, Internal medicine, RADIATION-THERAPY, Biomarkers, Tumor, medicine, Humans, Protein Kinase Inhibitors, Crizotinib, business.industry, ResearchInstitutes_Networks_Beacons/mcrc, CONCURRENT, medicine.disease, Clinical trial, Radiation therapy, 030104 developmental biology, CLINICAL-PRACTICE, Mutation, business, SINGLE-CENTER
Abstract

Background: Brain metastases (BM) are frequent in non-small cell lung cancer (NSCLC) patients, but there is a lack of evidence-based management of this patient group. We aimed to capture a snapshot of routine BM management in Europe to identify relevant research questions for future clinical trials. Methods: An EORTC Lung Cancer Group (LCG) online survey containing questions on NSCLC BM screening and treatment was distributed between 16/02/17 and 15/06/17 to worldwide EORTC LCG members, and through several European scientific societies in the thoracic oncology field. Results: A total of 462 European physician responses (394 institutions) were analysed (radiation oncologist: 53% [n = 247], pulmonologist: 26% [n = 119], medical oncologist: 18% [n = 84]; 84% with >5 years' experience in NSCLC). Italy (18%, n = 85), Netherlands (15%, n = 68), UK (14%, n = 66), and France (12%, n = 55) contributed most. 393 physicians (85%) screened neurologically asymptomatic patients for BM at diagnosis (52% using magnetic resonance imaging). Most often screened patients were those with a driver mutation (MUT+; 51%, n = 234), stage III (63%, n = 289), and IV (43%, n = 199). 158 physicians (34%) used a prognostic classification to guide initial treatment decisions, and in 50%, lowest prognostic-score threshold to receive treatment differed between MUT+ and non-driver mutation (MUT-) patients. MUT+ patients with >4 BM were more likely to receive stereotactic radiosurgery (SRS) compared with MUT- (27% versus. 21%; p < 0.01). Most physicians (90%) had access to SRS. After single BM surgery, 50% systematically prescribed SRS or WBRT, and 45% only in case of incomplete resection. The preferred treatment in neurologically asymptomatic treatment-naive patients diagnosed with >5 BM was systemic treatment (79%). Of all, 45%/49% physicians stated that all tyrosine kinase inhibitors and immune checkpoint blockers were discontinued (timing varied) during SRS/WBRT, respectively. Drugs most often continued during SRS/WBRT were erlotinib (44%/40%), gefitinib (39%/34%), afatinib (29%/25%), crizotinib (33%/26%) and anti-PD-(L)-1 (28%/22%). Conclusion: BM management is highly variable in Europe: screening is not uniform, prognostic classifications are not often used and MUT+ NSCLC patients generally receive more intensive local treatment. Prospective assessment of BM management in MUT+ NSCLC patients is required. (C) 2018 Elsevier Ltd. All rights reserved.

Published
2018
Full Text
View/download PDF

40. 9P Circulating tumour cells (CTCs) count and PD-L1 expression in untreated extensive small cell lung cancer patients treated in the REACTION trial, a phase II study of etoposide and cis/carboplatin with or without pembrolizumab (NCT02580994)

Author

Menis, J., primary, Bironzo, P., additional, Radj, G., additional, Greillier, L., additional, Monnet, I., additional, Livi, L., additional, Young, R., additional, Decroisette, C., additional, Cloarec, N., additional, Robinet, G., additional, Schott, R., additional, Califano, R., additional, De Marinis, F., additional, Mauer, M., additional, Pochesci, A., additional, Silva, M., additional, Caramella, C., additional, Dingemans, A-M., additional, Dive, C., additional, and Besse, B., additional

Published
2020
Full Text
View/download PDF

42. ID:2908 First-Line Nivolumab + Ipilimumab vs Chemotherapy in Unresectable Malignant Pleural Mesothelioma: CheckMate 743

Author

Baas, P., primary, Scherpereel, A., additional, Nowak, A., additional, Fujimoto, N., additional, Peters, S., additional, Tsao, A., additional, Mansfield, A., additional, Popat, S., additional, Jahan, T., additional, Antonia, S., additional, Oulkhouir, Y., additional, Bautista, Y., additional, Cornelissen, R., additional, Greillier, L., additional, Grossi, F., additional, Kowalski, D.M., additional, Rodriguez-Cid, J., additional, Aanur, P., additional, Baudelet, C., additional, and Zalcman, G., additional

Published
2020
Full Text
View/download PDF

43. 1389P IFCT-1602 CHIVA2 phase II trial: Nivolumab in previously treated HIV-patients with advanced non-small cell lung cancer (NSCLC)

Author

Lavole, A., primary, Mazieres, J., additional, Schneider, S., additional, Brosseau, S., additional, Kiakouama, L.M., additional, Greillier, L., additional, Guihot, A., additional, Abbar, B., additional, Baron, M., additional, Makinson, A., additional, Langlais, A., additional, Morin, F., additional, Spano, J-P., additional, and Cadranel, J., additional

Published
2020
Full Text
View/download PDF

44. LBA85 REACTION: A phase II study of etoposide and cis/carboplatin with or without pembrolizumab in untreated extensive small cell lung cancer

Author

Besse, B., primary, Menis, J., additional, Bironzo, P., additional, Gervais, R., additional, Greillier, L., additional, Monnet, I., additional, Livi, L., additional, Young, R., additional, Decroisette, C., additional, Cloarec, N., additional, Robinet, G., additional, Schott, R., additional, Califano, R., additional, De Marinis, F., additional, Banna, G.L., additional, Mauer, M., additional, Pochesci, A., additional, Hasan, B., additional, Berghmans, T., additional, and Dingemans, A-M.C., additional

Published
2020
Full Text
View/download PDF

45. 1411TiP GFPC 06-2018: A multicenter non-randomized phase II study evaluating platinum-pemetrexed-atezolizumab (+/-bevacizumab) for patients with stage IIIB/IV non-squamous non-small cell lung cancer with EGFR mutations, ALK rearrangement or ROS1 fusion progressing after targeted therapies

Author

Bylicki, O., primary, Clarisse, B., additional, Grellard, J-M., additional, Swalduz, A., additional, Castera-Tellier, M., additional, Ferlandin, S., additional, Monnet, I., additional, Greillier, L., additional, Descourt, R., additional, Peron, J., additional, Chouaid, C., additional, and Gervais, R., additional

Published
2020
Full Text
View/download PDF

47. 1279P Impact of KRAS mutations and subtypes on efficacy of immune-checkpoint inhibitors (ICI) in non-small cell lung cancer (NSCLC)

Author

Mazieres, J., primary, Tomasini, P., additional, Lusque, A., additional, Boucekine, M., additional, Gautschi, O., additional, Cortot, A.B., additional, Couraud, S., additional, Thai, A., additional, Ng, T., additional, Greillier, L., additional, Veillon, R., additional, Neal, J.W., additional, Popat, S., additional, Gounant, V., additional, Mhanna, L., additional, Drilon, A., additional, Baron, J. Milia, additional, and Barlesi, F., additional

Published
2020
Full Text
View/download PDF

48. 559P Phase Ib study of CC-90011 plus etoposide and cisplatin (EP) in patients with first-line extensive-stage (ES) small cell lung cancer (SCLC)

Author

Paz-Ares, L., primary, Juan-Vidal, O., additional, Carcereny, E., additional, Greillier, L., additional, Navarro, A., additional, Bennouna, J., additional, Santoro, A., additional, Berardi, R., additional, Besse, B., additional, Salvagni, S., additional, Gonzalez, H., additional, de Alvaro, J., additional, Parra-Palau, J., additional, Sánchez-Pérez, T., additional, Aronchik, I., additional, Filvaroff, E., additional, Lamba, M., additional, Nikolova, Z., additional, and Ponce, S., additional

Published
2020
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results